Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02699554 · ClinicalTrials.gov registry record
Quantifying Patient-Specific Changes in Neuromuscular Control in Cerebral Palsy
A clinical trial, sponsored by University of Washington.
- Completed
- Registry status
- 55
- Enrollment target
NCT02699554: Completed study, sponsored by University of Washington.
NCT02699554 is a clinical trial that has completed, run by University of Washington. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02699554 has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
Impaired neuromuscular control hinders movement for individuals with cerebral palsy and other neurological disorders. In this research, the investigators are developing new tools to quantify impaired neuromuscular control in cerebral palsy and evaluate changes after one of the most common treatments, orthopaedic surgery. The results from this research will empower clinicians to identify patient-specific factors that contribute to impaired movement and improve treatment and quality of life.
Primary Outcome
The Walk Dynamic Motor Control Index (Walk DMC) is a specific measurement calculated from electromyography during gait using nonnegative matrix factorization. A value of 100 indicates complexity of neuromuscular control similar to typically-developing peers and each 10 point deviation represents one standard deviation from typically-developing peers. Thus, a value of 80 would indicate that an individual's muscle coordination during gait is two standard deviations below the complexity of unimpair
Interventions
- PROCEDURE Single-event multilevel surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-09 |
| Est. Completion | 2020-09 |
What the finished NCT02699554 record still lists
NCT02699554 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Single-event multilevel surgery is the first listed.
NCT02699554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02699554 about?
NCT02699554 is a clinical study titled "Quantifying Patient-Specific Changes in Neuromuscular Control in Cerebral Palsy". Impaired neuromuscular control hinders movement for individuals with cerebral palsy and other neurological disorders. In this research, the investigators are developing new tools to quantify impaired neuromuscular control in cerebral palsy and evaluate changes after one of the most common treatments...
What is the current status of trial NCT02699554?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2015-09. Estimated completion is 2020-09.
What interventions are being tested in trial NCT02699554?
The interventions under investigation include: Single-event multilevel surgery (PROCEDURE).
Who is sponsoring clinical trial NCT02699554?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia